DEPO-SUBQ PROVERA 104

Pfizer Inc

Revision date : 2007-01-02

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating
Safety risk rating
Environmental risk rating

General Information

Version

1.1

Revision date

2007-01-02

Product name

DEPO-SUBQ PROVERA 104

Product Synonyms

DMPA-SC

Chemical name

Mixture

1.2.1 Relevant identified uses

Pharmaceutical product used as contraceptive agent

Emergency telephone

1-800-424-9300, +44 (0)208 762 8322

Icons in SDS

Company Information

company name

Pfizer Inc

Section 2

Hazardous Ingredients

CAS Number EU EINECS List % Medroxyprogesterone acetate 71-58-9 200-757-9 15 Hydrogen chloride 7647-01-0 231-595-7 ** Sodium hydroxide 1310-73-2 215-185-5 ** Sodium chloride 7647-14-5 231-598-3 Ingredient CAS Number EU EINECS List % Methionine 63-68-3 200-562-9 * Povidone 9003-39-8 Not listed * Sodium phosphate, dibasic 7558-79-4 231-448-7 * Polysorbate 80 9005-65-6 Not listed * Sodium phosphate, monobasic 7558-80-7 231-449-2 * Methylparaben 99-76-3 202-785-7 * Water for injection 7732-18-5 231-791-2 * Polyethylene glycol 25322-68-3 Not listed * Propylparaben 94-13-3 202-307-7 *

Additional information

* Proprietary ** to adjust pH Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. 3. HAZARDS IDENTIFICATION Appearance: White to off-white suspension Signal Word: DANGER Statement of Hazard: Possible carcinogen May cause harm to the unborn child. May cause reproductive system effects Additional Hazard Information: Short Term: Not expected to cause eye irritation. (based on components) . Active ingredient is not a skin irritant . Not acutely toxic (based on animal data) . May be absorbed through the skin and cause systemic effects. Long Term: The use of oral contraceptives is associated with increased risk of myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease. Known Clinical Effects: Adverse effects associated with the therapeutic use of medroxyprogesterone acetate include menstrual irregularities, abdominal pain or discomfort weight changes, dizziness, headache, weakness or fatigue, and nervousness. EU Indication of danger: Toxic to reproduction: Category 1 Carcinogenic: Category 2 EU Hazard Symbols: EU Risk Phrases: R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn child. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.